Nppb Blocking Agents for Pruritus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic itch conditions, such as those associated with psoriasis, atopic dermatitis, and systemic conditions like renal failure, are inadequate, as existing therapies often fail to effectively manage pruritus, leading to a significant reduction in quality of life.
Innovation Solution
Administering a natriuretic polypeptide B (Nppb) blocking agent, which can be an antagonist, inhibitor, or antagonist conjugate, to block Nppb activity, thereby reducing or preventing itch in mammals by inhibiting Nppb signaling or production, using methods like nucleic acid interference or receptor antagonism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat chronic itch conditions, then treatment is provided, but the therapies fail to effectively manage pruritus
Solution Approach 1:
The patent extracts and targets the specific molecular pathway (Nppb signaling) that mediates itch transmission. By using Nppb blocking agents that specifically inhibit this pathway, the treatment isolates the therapeutic action to the relevant biological mechanism, improving effectiveness without affecting other physiological processes.
Solution Approach 2:
The patent changes the therapeutic parameter from general anti-itch mechanisms to specific Nppb pathway inhibition. By targeting the Nppb-Npral signaling axis with selective blocking agents, the treatment achieves superior itch management through precise molecular parameter control rather than broad-spectrum approaches.
2Reliability
If Nppb blocking agents are administered to block Nppb activity, then itch is reduced or prevented, but potential neurotoxicity may occur
Solution Approach 1:
The patent applies local quality by designing blocking agents with specific affinity for the Npral receptor isoform expressed in itch-sensing neurons. This selective binding ensures that the therapeutic effect is localized to pruritus pathways while sparing other neural functions, thereby reducing neurotoxicity risk.
Solution Approach 2:
The patent uses Nppb blocking agents as intermediary molecules that specifically intercept the Nppb-Npral signaling interaction. These agents act as selective mediators that block itch transmission without disrupting other neurotransmitter systems, reducing the risk of neurotoxic side effects.
Data Source
AI summary
Disclosed is a method of treating, reducing, or preventing pruritis in a mammal, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to a mammal in an amount effective to treat or prevent pruritis in the mammal. An in vitro method of identifying a compound that inhibits Nppb activity is also disclosed.